Mgc Pharmaceuticals Share Price and Company Fundamentals

-0.001 (-1.695%)
52 week
0.02 - 0.13

Last traded: Last Friday at 6:10 AM

MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesMGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines.
Industry / SectorDrug Manufacturers—Specialty & Generic / Healthcare
Mailing address1202 Hay Street West Perth WA 6005 Australia
Phone / Fax61 8 6382 3390 /


Mgc Pharmaceuticals does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Mgc Pharmaceuticals.

NameTitleAgeTotal Pay
Mr. Brett Anthony Mitchell B.Ec., MAICDExec. Chairman47260.53k
Mr. Roby Reuven ZomerCo-Founder, CEO, MD & Exec. Director348.53k
Mr. Nativ SegevFounder & Non-Exec. Director324.04k
Mr. Daniel KendallChief Financial Officer
Dr. Nadya LisodoverChief Research Officer
Mr. Amir PolakCTO & Head of Pharmaceutical Production
Ms. Nicole GodresseGlobal Chief Sales Officer
Ms. Sabina SuljakovicHead of the Quality Assurance Department
Ms. Rachel Jelleff KerrCompany Sec. (Leave of Absence)
Hugh WintersChief Exec. Officer of MGC Derma

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Mgc Pharmaceuticals is 139.4M and its enterprise value is 131.07M. The enterprise value to revenue ratio of MXC is 44.24.

The MXC's stocks Beta value is 1.53 making it 53% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Mgc Pharmaceuticals (MXC)

Mgc Pharmaceuticals (ASX:MXC) Frequently Asked Questions

1. What is Mgc Pharmaceuticals's Stock Symbol?

Mgc Pharmaceuticals trades on ASX under the ticker symbol "MXC".

2. What is Mgc Pharmaceuticals's stock price today?

One share of MXC stock can currently be purchased for approximately $0.058.

3. How can I contact Mgc Pharmaceuticals?

Mgc Pharmaceuticals's mailing address is 1202 Hay Street West Perth WA 6005 Australia. The company can be reached via phone at 61 8 6382 3390.

4. What is Mgc Pharmaceuticals's official website?

The official website of Mgc Pharmaceuticals is

5. Which share registry manages Mgc Pharmaceuticals's stock?

Mgc Pharmaceuticals's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.